References
- MA Pfaller. (1998). The epidemiology of invasive mycoses-narrowing the gap. Clin Infect Dis 27:1148–1150.
- KA Marr, RA Carter, F Crippa, A Wald, and L Corey. (2002). Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients. Clin Infect Dis 34:909–917.
- S Hood, and DW Denning. (1996). Treatment of fungal infection in AIDS. J Antimicrob Chemoth 37:71–85.
- M Masia Canuto, and F Gutierrez Rodero. (2002). Antifungal drug resistance to azoles and polyenes. Lancet Infect Dis 2:550–563.
- CR Sims, L Ostrosky-Zeichner, and JH Rex. (2005). Invasive candidiasis in immunocompromised hospitalized patients. Arch Med Res 36:660–671.
- P Montravers, and K Jabbour. (2006). Managing the challenges of invasive fungal infections. Int J Antimicrob Agents 27:1–2.
- BD Alexander, and JR Perfect. (2000). Antifungal resistance trends towards the year 2000 implications for therapy and new approaches. Drugs 54:657–678.
- N Lebouvier, F Pagniez, M Duflos, P Le Pape, YG Min Na, L Bauta, and ML Borgnea. (2007). Synthesis and antifungal activities of new fluconazole analogues with azaheterocycle moiety. Bioorg Med Chem Lett 17:3686–3689.
- JR Rees, RW Pinner, and RA Hajjeh. (1993). The epidemiological features of invasive mycotic infections in the San Francisco Bay Area, 1992–1993: Results of population-based laboratory active surveillance. Clin Infect Dis 27:1138–1140.
- A Polak. (1999). The past, present and future of antimycotic combination therapy. Mycoses 42:355–370.
- R Musiol, J Jampilek, V Buchta, L Silva, H Niedbala, B Podeszwa, A Palka, K Majerz-Maniecka, B Oleksynd, and J Polanski. (2006). Antifungal properties of new series of quinoline derivatives. Bioorg Med Chem 14:3592–3598.
- DJ Sheehan, CA Hitchcock, and CM Sıbley. (1999). Current and emerging azole antifungal agents. Clin Microbiol Rev 12:40–79.
- H Yamaguchi. (1977). Antagonistic action of lipid components of membranes from Candida albicans and various other lipids on two imidazole antimycotics, clotrimazole and miconazole. Antimicrob Agents Chemother 12:16–25.
- H Yamaguchi. (1978). Protection by unsaturated lecithin against the imidazole antimycotics, clotrimazole and miconazole. Antimicrob Agents Chemother 13:423–426.
- P Vicini, F Zani, P Cozzini, and I Doytchinova. (2002). Hydrazones of 1,2-benzisothiazole hydrazides: Synthesis, antimicrobial activity and QSAR investigations. Eur J Med Chem 37:553–564.
- KA Metwally, LM Abdel-Aziz, EM Lashine, MI Husseiny, and RH Badawy. (2006). Hydrazones of 2-aryl-quinoline-4-carboxylic acid hydrazides: Synthesis and preliminary evaluation as antimicrobial agents. Bioorg Med Chem 14:8675–8682.
- A Gürsoy, N Terzioğlu, and G Ötük. (1997). Synthesis of some new hydrazide-hydrazones, thiosemicarbazides and thiazolidinones as possible antimicrobials. Eur J Med Chem 32:753–757.
- HL Yale, K Losen, J Martins, M Holsing, MF Perry, and J Bernstein. (1953). Chemotherapy of experimental tuberculosis. VIII. The synthesis of acid hydrazides, their derivatives and related compound. J Am Chem Soc 75:1933–1942.
- L Bukowski, and M Janowiec. (1996). 1-Methyl-1H-2-imidazo[4,5-b]pyridinecarboxylic acid and of its derivatives with suspected antituberculotic activity. Pharmazie 51:27–30.
- NCCLS. Reference method for broth dilution antifungal susceptibility testing of yeasts; approved standardsecond ed.. (2002). NCCLS document M27-A2 [ISBN 1-56238-469-4].